William Blair analyst Andy Hsieh has maintained their bullish stance on CRDF stock, giving a Buy rating on May 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors surrounding Cardiff Oncology’s promising developments with onvansertib. The recent abstracts released for the 2025 ASCO annual meeting highlight onvansertib’s potential in treating metastatic triple-negative breast cancer and frontline pancreatic cancer. These investigator-sponsored trials suggest that onvansertib could be expanded into new indications efficiently, which is a strategic move by the company.
Furthermore, the initial results from the Phase II CRDF-004 study underscore onvansertib’s transformative potential in treating RAS mutation-positive metastatic colorectal cancer. This positions Cardiff Oncology at a pivotal moment where the risks associated with onvansertib have been sufficiently mitigated to justify significant investment. The potential for onvansertib to extend its application beyond colorectal cancer into other cancer types, such as pancreatic and breast cancer, presents multiple blockbuster opportunities, reinforcing Cardiff’s status as a top investment idea in the coverage universe.
According to TipRanks, Hsieh is a 4-star analyst with an average return of 5.4% and a 44.81% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Skye Bioscience, Lantheus, and Altimmune.
In another report released on May 9, Craig-Hallum also reiterated a Buy rating on the stock with a $10.00 price target.